Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 6/20 | 0.49 |
| ▸ | CNR1 | P21554 | 5/20 | 0.49 |
| ▸ | DGAT2 | Q96PD7 | 2/20 | 0.48 |
| ▸ | PBK | Q96KB5 | 5/20 | 0.48 |
| ▸ | DRD4 | P21917 | 1/20 | 0.46 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10107496 | 0.93 | CNR2 (0.54) | CNR2CNR1DGAT2MEN1KMT2A | |
| SCHEMBL1753334 | 0.88 | CNR2 (0.55) | CNR2CNR1MEN1KMT2ARAB9A | |
| SCHEMBL23201613 | 0.83 | DGAT2 (0.51) | CNR2CNR1DGAT2PBKMEN1 | |
| SCHEMBL1753490 | 0.80 | DRD4 (0.55) | DRD4MEN1KMT2ARAB9AMAPK1 | |
| SCHEMBL10107630 | 0.80 | CNR2 (0.51) | CNR2CNR1DGAT2RAB9A | |
| SCHEMBL11814700 | 0.78 | CHRM1 (0.53) | CNR2CNR1MEN1KMT2A | |
| SCHEMBL30843806 | 0.77 | CHRM1 (0.53) | — | |
| SCHEMBL29280924 | 0.77 | CHRM1 (0.53) | — | |
| SCHEMBL14477851 | 0.76 | PARP1 (0.46) | DGAT2PBKDRD4PARP1MAPK1 | |
| SCHEMBL14477850 | 0.76 | PARP1 (0.46) | DGAT2PBKDRD4PARP1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158783-B2 | MTP inhibiting tetrahydro-naphthalene-1-carboxylic acid derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-04-17 | — | — | US | disclosed |
| US-8158783-B2 | MTP inhibiting tetrahydro-naphthalene-1-carboxylic acid derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-04-17 | — | — | US | disclosed |
| US-20100016291-A1 | MTP INHIBITING TETRAHYDRO-NAPHTHALENE-1-CARBOXYLIC ACID DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-01-21 | — | — | US | disclosed |
| US-20100016291-A1 | MTP INHIBITING TETRAHYDRO-NAPHTHALENE-1-CARBOXYLIC ACID DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016291-A1 | MTP INHIBITING TETRAHYDRO-NAPHTHALENE-1-CARBOXYLIC ACID DERIVATIVES | PNLIP, APOB, MTPN | CNR2 2151/4885CNR1 2051/4885DGAT2 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.